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An equilibrium between cell gain via mitosis and loss by apoptosis
influences structure, pattern and function of many tissues, but may
become deranged in cancer. While mutations, rearrangements and
deletions of specific growth regulatory genes are prerequisite to
malignant change (Fearon and Vogelstein, 1990), the principal
abnormalities leading to loss of growth homeostasis in colorectal
cancer are unclear. The p53 protein is active as a transcription
factor (Bargonetti et al, 1991) and exerts G1 checkpoint control
(Kastan et al, 1991; El-Deiry et al, 1993) or initiates apoptosis
(Shaw et al, 1992), particularly in response to DNA damage
(Clarke et al, 1993). Functional inactivation of p53 promotes
genomic instability (Bischoff et al, 1990) and is commonly, though
not universally, associated with intracellular p53 protein accumu-
lation (Hall and Lane, 1994; Save et al, 1998). p53 accumulation is
detectable in many colorectal cancers (Purdie et al, 1991; Scott et
al, 1991), with 40–60% having immunologically detectable levels
(Kang et al, 1997; Ahnen et al, 1998). However, effects on growth
homeostasis are unclear.
Previous studies investigated relationships between p53 over-
expression, proliferation and apoptosis in colorectal cancer by in
situ techniques viz immunohistochemistry, in-situ TUNEL assay
of apoptosis, or histological assessment of apoptotic bodies, in
fixed tissue sections. p53 overexpression was found to be associ-
ated with a lower apoptotic index (Kobayashi et al, 1995). In
support of this finding, p53-negative tumours from patients aged
less than 45 years were found to have higher apoptotic body
counts (Langlois et al, 1997). However, Tsujitani et al (1996)
reported converse findings in 67 colorectal tumours and found no
correlation between p53 expression and apoptosis. Two studies
found no relationship between p53 overexpression and Ki-67
expression (Lanza et al, 1996; Tsujitani et al, 1996).
While histological assay of cell cycle antigens, apoptotic bodies
or other in-situ assays of apoptosis in paraffin-embedded tissues
are useful, they provide subjective and semiquantitative data.
Interpretation differences could account for some variance in the
previous reports. Optimal analysis of proliferative indices may be
obtained from the examination of whole cell preparations from
unfixed tissues, by flow cytometry (Shankey et al, 1993). This
technique provides objective measurement of cell cycle phase
fractions and may also use a modification of the TUNEL assay to
assess apoptosis. In the present study, these methods were used to
assay cell cycle phase distribution and apoptosis, in 42 fresh
primary colorectal tumours and matched normal mucosa samples.
p53 accumulation was assayed in fixed sections by immunohisto-
chemistry. We sought to test the hypothesis that p53 accumulation
in colorectal cancer is accompanied by disturbance of growth
homeostasis. To test this hypothesis, we investigated relationships
between p53 accumulation, proliferation, apoptosis, in colorectal
cancers and in uninvolved mucosa.
PATIENTS AND METHODS
Retrieval of tissue
Fresh mucosal and tumour specimens were obtained immediately
after colectomy from 42 consecutive patients with colorectal
carcinoma, who were recruited from South Cleveland Hospital,
Middlesbrough, the Royal Victoria Infirmary, Newcastle upon
Tyne and some from Ninewells Hospital, Dundee. No patients had
received preoperative radio- or chemotherapy. All patients gave
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informed consent to the study. Clinical data, including symptomatic
presentation, age, family history, site of tumour and operation
type were recorded. Tumour samples of approximately 1 g were
removed without compromise to histopathological assessment.
Normal mucosa was isolated from the same surgical specimens,
distant from the tumours. Samples were then labelled and snap-
frozen in liquid nitrogen, to enable transport to the laboratory.
Colectomy specimens underwent histopathological assessment of
differentiation, depth of invasion, lymph node metastases and
resection margins. Blocks of fixed tumour were mounted in
paraffin and sections cut for immunohistochemistry.
Preparation of primary colorectal tumour tissue
Specimens of matched mucosa and tumour were rapidly thawed,
finely minced, placed in Isoton II (Coulter Electronics, Luton,
Table 1 No relationship found between p53 accumulation, DNA ploidy, DNA S phase fraction or Dukes’ stage of colorectal cancer (P = NS)




Positive 22 59 16 6 15.7 ± 14 1 14 7
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Figure 1 (A) DNA synthesis (S) phase fractions of colorectal mucosal and tumour specimens. P < 0.02 by Wilcoxon matched pairs signed-rank test.
Horizontal bar indicates median. (B) Percentage of cells showing apoptosis by TUNEL assay, in normal mucosa and colorectal tumours. P < 0.01 by Wilcoxon
matched pairs signed-rank test. Median shown by horizontal bar. (C) Relationship between apoptosis and DNA S phase fraction in normal mucosa. (r = 0.8;
P < 0.05 by Pearson test). (D) Percentage of cells showing apoptosis and proliferation in colorectal cancers. No relationship was observed1064 DS Watson et al
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Bedfordshire, UK) and mechanically disaggregated by passing
through a fine wire mesh (~50 mm), as previously described
(Brotherick et al, 1995). The resulting single-cell suspension was
centrifuged at 400 g and the cell pellet resuspended in 10 ml of
Isoton II. The cell concentration was assessed by haemocytometer
and diluted to approximately 1 ´ 106 cells per ml. The cell suspen-
sion was divided into two equal portions, one for assessment of
cellular DNA content and cell cycle phase fractions and one for the
apoptosis assay. We have previously used cytokeratin gating in
disaggregated breast cancers after saponin treatment to render cells
permeable to antibodies (Brotherick et al, 1998). However, cyto-
keratin gating and assay of apoptosis in the same sample by the
method of the present study is not possible. The APO-Direct kit
(Pharmingen) provides a fluorescein isothiocyanate (FITC)–dUTP
label that identifies DNA strand-breaks. The preparation method
requires fixation and permeabilization of cells, which precludes
reliable assay of cytoplasmic markers. Furthermore, the FITC–
dUTP of the APO-Direct kit and commercially available labelled
anticytokeratin antibodies have emission spectra of the same
wavelength and cannot be assessed in the same sample. We there-
fore used singlet discrimination gating method only, to focus on
cells of interest. This technique allows exclusion of cell doublets,
triplets, aggregates or clumps. The total tumour cell population
was assayed in this study.
Calibration of flow cytometer
Flow cytometry was carried out using a FACScan (Becton
Dickinson, Oxford, Oxfordshire, UK). Linearity of the amplifier
and FACScan settings for fluorescence channel 1 (FL1, green) and
2 (FL2, red) were checked using standardized beads. Healthy
human lymphocytes were isolated from peripheral blood and
suspended in medium at 106 cells per ml. These provided a normal
control diploid cell population and were used for standardization
of instrument settings. Aliquots (200 ml) were incubated at 4°C for
1 min with 10 ml of propidium iodide (PI, 0.25 mg ml–1; Sigma) in
4.5% (v:v) Triton X-100 (non-fluorescent cytometry grade; BDH,
Poole, Dorset, UK). RNAase (Sigma) 1 mg ml–1 was added to
remove cellular RNA, which may produce an associated fluores-
cent signal. Fluorescence of the nuclei was measured in the red
spectrum using a 630 nm filter on the fluorescence 2 photomulti-
plier tube of the instrument. Linear amplification was from
prestored instrument settings. The G0/G1 peak of freshly isolated
lymphocytes was adjusted in the fluorescence 2 red spectrum to
channel 100.
Assay of tumour and mucosal cellular DNA content
Cell suspensions were diluted to 1 ´ 106 cells per ml, processed
and analysed as above to assay DNA content. Then, 1 ´ 105 events
were recorded for each specimen.
Data analysis
DNA histograms were constructed and cell cycle phase fractions,
and the presence of aneuploidy were assessed using Multicycle AV
(Coulter) computer software, using previously described methods
(Herman, 1992). DNA aneuploidy was identified only when two
or more distinct (bimodal) peaks were present (Shankey et al,
1993). The percentage of cells in S phase was taken as an index of








































Figure 2 Flow cytometric dot-plots of apoptosis vs DNA, for: (A) positive control cells; (B) negative control cells; (C) sample of colorectal mucosa; (D) sample
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Assessment of apoptosis
In cells undergoing apoptosis, DNA is degraded by nucleases with
exposure of multiple 3´-hydroxyl termini. These exposed termini
may be detected by the TUNEL (terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end-labelling) assay which identifies
exposed termini. This method has been adapted for flow cytometry
by Li et al (1995), to provide a quantitative assay of apoptosis.
Cell suspensions were centrifuged at 400 g and the supernatants
discarded. Cells were fixed by incubation with 5 ml of 1%
paraformaldehyde in Isoton II at 4°C for 15 min. The suspensions
were centrifuged, the supernatants discarded and the cells washed
with Isoton II twice. Five millilitres of ice-cold 70% (v/v) ethanol
was added to each sample, which were then stored at –20°C
overnight. DNA strand-breaks consistent with apoptosis, were
assayed by TUNEL labelling, using the APO-DIRECTTM kit
(Pharmingen, San Diego, CA, USA) which includes positive (i.e.
apoptotic) and negative (i.e. non-apoptotic) control cell samples,
prepared from the HL-60 human lymphoma cell line. Apoptosis
was induced in the positive control cell line by treatment with
Camptothecin. Negative control cells were untreated.
Suspensions of positive and negative control cells, mucosal and
tumour cells were spun at 1000 g and the supernatants discarded,
then washed twice in buffered saline. A staining solution was
prepared using kit reagents, with terminal deoxynucleotidyl trans-
ferase (TdT) and fluorescein-tagged deoxyuridine triphosphate
nucleotides (FITC-dUTP) in buffered saline. Fifty microlitres of
the above solution was added to each cell pellet, vortexed gently
then incubated at 37°C for 3 h. Buffered saline rinse (1 ml) was
added to each suspension, spun at 1000 g and the supernatant
discarded. The rinse was repeated, then samples were resuspended
in a 0.5 ml solution of PI (0.01 mg ml–1; Sigma) and RNAase
(0.05 mg ml–1; Sigma). The cells were incubated at room tempera-
ture for 30 min, then subjected to analysis of fluorescence by flow
cytometry. A FACScan flow cytometer (Becton Dickinson) was
used to measure the fluorescence of 1 ´ 105 cellular events.
Nuclear DNA content was assayed on the fluorescence 2 setting
while FITC-labelled DNA breaks were assayed on fluorescence 1.
Flow cytometry analysis
Fluorescence data were analysed using LYSYS II software
(Becton Dickinson). Nuclear doublets and other multiples were
excluded from analysis by setting a gate using a dot-plot of fluor-
escence 2 width against fluorescence 2 area. For each sample, a
histogram of fluorescence 1 was constructed. A marker was placed
on the histogram for the negative control at the 97th percentile of
fluorescence, and the value of this level of fluorescence recorded.
A marker at this same level was applied to the other histograms,
and the percentage of cells above this level calculated. This
percentage of cells minus 3% was taken as the proportion of
positive cells.
Immunohistochemistry
Thirty-seven paraffin-embedded tumour specimens were available
for immunohistochemistry. Sections of 5-mm thickness were cut
and mounted on glass microscope slides, previously coated with
3-aminopropyl triethoxy-silane. Sections were dewaxed, soaked in
0.5% hydrogen peroxide in methanol and washed in cold water.
Antigen retrieval was performed by heating in a pressure cooker for
2 min in citrate buffer (pH 6.0) at boiling point. Following a 5-min
rinse in 0.005 M Tris-buffered saline (TBS), sections were covered
with normal rabbit serum diluted 1:10 in TBS (NRS). Excess serum
was removed and the sections were incubated consecutively with
three antisera for 30 min, with 2 ´ 5 min washes in TBS after each,
viz. (i) Novocastra DO7 monoclonal mouse anti-human antibody to
p53 protein (NCL-p53-DO7) diluted 1:50 with NRS; (ii) Dako
biotinylated rabbit anti-mouse antibody (E0354) diluted 1:500 with
NRS; and (iii) streptavidin with biotinylated horseradish per-
oxidase (Dako streptABComplex/HRP), diluted 1:100 with NRS.
Sections were incubated for 1 h. Peroxidase activity was developed
with 3,3¢-diaminobenzidine followed by a rinse in water.
Haematoxylin was used as a counterstain and the sections were
dehydrated and mounted in DePeX mounting medium (BDH).
Sections were examined by light microscopy and the proportion of
epithelial cells with nuclear staining calculated for each tumour by
one observer (DSW). Tumours with over 50% nuclear staining
were categorized as showing significant p53 accumulation in
accordance with previous definitions (Manne et al, 1997).
Statistical analysis
Descriptive statistics included the mean ± standard deviation
(s.d.). The Wilcoxon matched pairs signed-rank test and the
Mann–Whitney  U–Wilcoxon rank sum W-test were used to assess
cell cycle and apoptosis data in mucosal and tumour specimens.
The Pearson’s correlation test was used to investigate the relation-
ship between proliferation and apoptosis.
Ethics
Ethical approval for the study was granted by Ethical Committees
of Newcastle University and South Tees Acute Hospitals NHS
Trust, and by the Tayside Committee for Medical Ethics.
RESULTS
Clinical data
Forty-two patients were recruited into the study, 26 male and 16
female, with a mean age of 68 (range 49–79). Twelve tumours
were right-sided and 30 left-sided, of which 20 were from the
rectum.
DNA content, cell proliferation and ploidy
All tumours contained diploid cell populations, while 11 carci-
nomas also included aneuploid cell populations. The proportions
of cells in DNA S phase were similar in diploid (15.5 ± 12.9%)
and aneuploid (15.6 ± 13.0) tumour cell populations. Tumour cell
DNA S phase fraction was greater than that of normal mucosa
(10.3 ± 6.6%; P < 0.02, by Wilcoxon matched pairs signed-rank
test); (Figure 1A).
Apoptosis
In the positive control HL-60 lymphoma line, 30% cells showed
DNA strand-breaks indicative of apoptosis, consistent with
suppliers findings. Apoptosis was found in 0–57% of cells in
tumours and normal mucosa samples. A greater proportion of
normal mucosa cells showed positive TUNEL labelling than1066 DS Watson et al
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tumour cells (28.7 ± 17.9% mucosa vs 18.5 ± 17.0% tumours;
P < 0.01, by Wilcoxon matched pairs signed-rank test) (Figure
1B). Representative flow cytometric dot-plots of apoptosis, plotted
against DNA content, are shown in Figures 2 A–D.
Relationship between proliferation and apoptosis
A significant relationship was observed between apoptosis identi-
fied by TUNEL and cell cycle DNA S phase fraction, in normal
mucosa (r = 0.8; P < 0.05, Pearson’s correlation test). No relation-
ship was observed in tumour samples (Figure 1 C, D).
Tumour stage
Three tumours were Dukes’ stage A, 24 stage B and 15 C. No rela-
tionship was observed between tumour stage, apoptotic proportion
or tumour cell S phase fraction.
p53 immunohistochemistry
In 13 tumours, p53 immunostaining was undetected or involved
< 10% cells, while in two tumours, staining involved 10–30% cells.
p53 accumulation, defined as > 50% nuclear staining for p53, was
detected in 22/37 (59%) carcinomas (Figure 3 A, B and Figure 4).
Apoptosis was reduced in tumours showing p53 accumulation,
compared to both p53-negative tumours and non-malignant mucosa
(14.8 ± 15% p53 accumulation vs 26.3 ± 18% p53-negative
tumours;  P < 0.05 and 28.7 ± 17.9% mucosa; P < 0.05 both by
Mann–Whitney U–Wilcoxon rank sum W-test). Tumours without
p53 accumulation had apoptotic proportions indistinguishable from
mucosal samples. p53 accumulation was unrelated to ploidy, DNA
S phase fraction or Dukes’ stage (Table 1).
DISCUSSION
Mutation of the tumour suppressor p53 gene is a non-essential
event during human colorectal carcinogenesis (Baker et al, 1990)
and incurs loss of G1 checkpoint control to allow DNA repair
(Kastan et al, 1991) or initiate apoptosis (Shaw et al, 1992) in
response to DNA damage. These mechanisms may induce
genomic instability (Bischoff et al, 1990) and acquisition of the
multiple ‘hits’ required for cancer development (Nowell, 1976). In
established cancers, p53 inactivation is commonly associated with
intracellular p53 protein accumulation (Hall and Lane, 1994). The
present study has shown p53 accumulation in 59% of colorectal
tumours, in accord with previous findings (Kang et al, 1997;
Ahnen et al, 1998).
Optimal regulation of proliferation or cell death is central to tissue
integrity. This study found a significant relationship between DNA S
phase fraction and apoptosis indicative of growth homeostasis, in
normal human colorectal mucosa. No such relationship was found
in the colorectal cancers. When all cancers were considered, the
proportion of cells undergoing apoptosis was lower while the frac-
tion in DNA synthesis phase was higher than in normal mucosa. On
further analysis, however, it was found that the difference in apop-
tosis was largely confined to cancers with p53 accumulation. DNA S
phase fraction was unrelated to p53. The findings point to a growth
dysequilibrium associated with p53 accumulation.
A
B
Figure 3 (A) Colorectal carcinoma showing negative immunohistochemistry
for p53. (B) p53 accumulation in a colorectal carcinoma, identified by > 50%
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Figure 4 Histogram showing the numbers of cancers with different
proportions of nuclei with detectable p53Clonal divergence occurs within human colorectal cancers.
Mutant p53 promotes genomic instability (Bischoff et al, 1990)
and may facilitate ploidy change (Carder et al, 1993). Previous
studies have shown that inactivation of p53 precedes, and may
facilitate, emergence of multiple cell populations which differ in
DNA ploidy (Carder et al, 1995). The findings of the present study,
that p53 accumulation confers growth dysequilibrium and selec-
tion pressure, may enable expansion of these unstable clones. An
association between ploidy and p53 status in colorectal cancer has
been confirmed by previous studies. Attallah et al have shown
DNA aneuploidy in 75% of p53-positive colorectal tumours,
compared to only 64% in p53-negative cancers (Attallah et al,
1997). Tumour heterogeneity of aneuploidy has been described,
and sampling at a single site could produce an underestimation of
the true extent. This factor could account for the lower incidence
of aneuploidy in the present study, than reported by previous
authors (Carder et al, 1995; Attalah et al, 1997). The number of
aneuploid tumours in the present study was too small for investi-
gation of any relationship to p53 status.
Given the association between p53 accumulation, genomic
instability (Carder et al, 1993) and growth dysequilibrium shown
in this study, an association between p53 accumulation and prog-
nosis could be anticipated. In this context, previous studies have
reported different findings in colorectal cancer. Lehy et al reported
that immunohistochemical overexpression of p53 protein was an
independent prognostic indicator of poor survival in a study of 66
patients (Lehy et al, 1996). Conversely, Mulder et al, in a study of
109 colorectal carcinomas, found that immunohistochemical p53
expression was not a useful marker for long-term prognosis
(Mulder et al, 1995). In the present study, clinical follow-up was
for a short interval only and accurate prognostic assessment was
not possible. We found no relationship between p53 accumulation
and Dukes’ stage, however.
In summary, this study has confirmed loss of growth homeostasis
in colorectal cancer. p53 accumulation is accompanied by reduced
apoptosis which may confer a growth advantage. Further insight is
necessary concerning p53-dependent growth regulation and p53-
independent mechanisms of tumour behaviour, including invasion
or metastatic potential, which may also influence prognosis.
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